Cogent Biosciences On November 10, 2025, Cogent Biosciences (COGT) reported positive data from its Phase 3 PEAK trial of bezuclastinib plus sunitinib in patients with imatinib-resistant or intolerant Gastrointestinal Stromal Tumors (GIST). The combination reached a median progression free survival (mPFS) of 16.5 months compared to sunitinib monotherapy, which reached a mPFS of 9.2 months. The . . . This content is for paid subscribers. Please click here to subscribe or here to log in.